The widespread use of screening mammography increases the probability of detecting smaller cancers without a decline in the detection of large cancers.
A collaborative study among Harvard and Dartmouth researchers has found that the widespread use of screening mammography increases the probability of detecting smaller cancers that may not be clinically relevant, without a decline in the detection of large cancers. So the increased screening does not impact mortality from breast cancers, the study concludes, and warns about overdiagnosis.
A similar conclusion was drawn by Dr Rinaa Punglia, an oncologist at the Dana-Farber Cancer Institute, during her presentation at the 2014 annual meeting of the American Society of Clinical Oncology, who concluded that overdiagnosis eventually leads to overtreatment. This unnecesary exposure of the patient to toxic drugs also increases healthcare costs.
For the present study, published in JAMA Internal Medicine, the authors followed 53,207 women who were diagnosed with breast cancer in the year 2000 in the United States. The data were obtained from the SEER cancer registries submitted by 547 counties. The study covered the period January 1, 2000, to December 31, 2010, and the analysis was performed between April 2013 and March 2015. The health outcomes evaluated in the study were breast cancer incidence in 2000 and incidence-based breast cancer mortality during the 10-year follow-up. Incidence and mortality were calculated for each county and age adjusted to the US population.
While a positive correlation was observed between the extent of screening and breast cancer incidence, it wasn't so with breast cancer mortality. Addiitonally, increased screening raised the detection rate of smaller breast cancers (≤2 cm), but did not decline the detection of larger cancers (>2 cm). These findings, the authors conclude, indicate overdiagnosis of breast cancer. While mamography screening is necessary, the authors are of the opinion that it should be directed to patients who are at a high-risk of the disease. They also recommend watchful waiting without immediate active treatment in these individuals.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More